137 related articles for article (PubMed ID: 37776225)
1. Finding the balance between immunoparesis recovery and multiple myeloma responses after autologous stem cell transplantation in the era of maintenance therapy and novel drugs.
Gozzetti A; Bernareggi I; Sammartano V
Br J Haematol; 2023 Dec; 203(5):706-707. PubMed ID: 37776225
[No Abstract] [Full Text] [Related]
2. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation.
Gao W; Li J; Wu Y; Li Y; Leng Y; Liu A; Yang G; Tian Y; Wang H; Wang G; Wu Z; Ren Z; Chen W
Ann Hematol; 2019 May; 98(5):1177-1184. PubMed ID: 30610278
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
4. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
5. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.
Chen Y; Chen Z; Cao J; Lin L; Li J
Hematology; 2024 Dec; 29(1):2329378. PubMed ID: 38470208
[TBL] [Abstract][Full Text] [Related]
6. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.
Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Tay J; Bahlis N
Leuk Lymphoma; 2018 Aug; 59(8):1920-1926. PubMed ID: 29160734
[TBL] [Abstract][Full Text] [Related]
7. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
Dávila J; González-Calle V; Escalante F; Cerdá S; Puig N; García-Sanz R; Bárez A; Montes C; López R; Alonso JM; Aguilar C; García-Mateo A; Labrador J; Aguilera C; García-Coca A; Hernández R; Mateos MV; Ocio EM
Br J Haematol; 2022 Jul; 198(2):278-287. PubMed ID: 35383901
[TBL] [Abstract][Full Text] [Related]
8. [Consolidation and maintenance therapy after autologous hematopoietic stem cell transplantation].
Ito S; Asahi M
Nihon Rinsho; 2015 Jan; 73(1):102-6. PubMed ID: 25626313
[TBL] [Abstract][Full Text] [Related]
9. Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Chong CY
Clin J Oncol Nurs; 2022 Jun; 26(3):252-256. PubMed ID: 35604735
[TBL] [Abstract][Full Text] [Related]
10. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T; Dytfeld D; Wróbel T; Jamroziak K; Robak P; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Zaucha JM; Mikulski D; Czabak O; Lahoud OB; Stefka A; Derman BA; Jakubowiak AJ
Br J Haematol; 2023 Dec; 203(5):792-802. PubMed ID: 37691005
[TBL] [Abstract][Full Text] [Related]
12. Have drug combinations supplanted stem cell transplantation in myeloma?
Palumbo A; Cavallo F
Blood; 2012 Dec; 120(24):4692-8. PubMed ID: 22730541
[TBL] [Abstract][Full Text] [Related]
13. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
[TBL] [Abstract][Full Text] [Related]
15. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
16. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
Davis JA; Thurlapati A; Weeda E; Gaffney KJ; Smith D; Maldonado A; Granger K; Martin KE; Williams YM; Herrington T; Velayati A; Bakos JK; Green K; Hashmi H
Ann Hematol; 2024 Jan; 103(1):251-258. PubMed ID: 37851073
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
18. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
[TBL] [Abstract][Full Text] [Related]
19. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison SJ; Mollee P; Roberts AW; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Jan; 45(1):94-105. PubMed ID: 25582938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
